Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.

Marqueen KE, Waingankar N, Sfakianos JP, Mehrazin R, Niglio SA, Audenet F, Jia R, Mazumdar M, Ferket BS, Galsky MD.

JNCI Cancer Spectr. 2018 Nov;2(4):pky075. doi: 10.1093/jncics/pky075. Epub 2019 Jan 28.

2.

Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma.

Beksac AT, Bicak M, Paranjpe I, Paulucci DJ, Sfakianos JP, Badani KK.

Clin Genitourin Cancer. 2018 Dec 8. pii: S1558-7673(18)30644-X. doi: 10.1016/j.clgc.2018.12.002. [Epub ahead of print]

PMID:
30639042
3.

Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses.

Chong JT, Paulucci D, Lubin M, Beksac AT, Gin G, Sfakianos JP, Badani KK.

Ther Adv Urol. 2018 Nov 9;10(12):383-391. doi: 10.1177/1756287218810313. eCollection 2018 Dec.

4.

A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE.

Urol Oncol. 2019 Feb;37(2):116-122. doi: 10.1016/j.urolonc.2018.11.011. Epub 2018 Dec 1.

PMID:
30509868
5.

Image guidance in robot-assisted radical prostatectomy: how far do we stand?

Martini A, Wagaskar VG, Dell'Oglio P, Rastinehad AR, Sfakianos JP, Tewari AK.

Curr Opin Urol. 2019 Jan;29(1):10-13. doi: 10.1097/MOU.0000000000000565.

PMID:
30489328
6.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
7.

Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device.

Ghanaat M, Winer AG, Sjoberg DD, Poon BY, Kashan M, Tin AL, Sfakianos JP, Cha EK, Donahue TF, Dalbagni G, Herr HW, Bochner BH, Vickers AJ, Donat SM.

Urology. 2018 Dec;122:121-126. doi: 10.1016/j.urology.2018.09.010. Epub 2018 Sep 20.

PMID:
30244117
8.

Risk factors and prognostic implications for pathologic upstaging to T3a after partial nephrectomy.

Beksac AT, Paulucci DJ, Gul Z, Reddy BN, Kannappan M, Martini A, Sfakianos JP, Gin GE, Abaza R, Eun DD, Bhandari A, Hemal AK, Porter J, Badani KK.

Minerva Urol Nefrol. 2018 Sep 19. doi: 10.23736/S0393-2249.18.03210-1. [Epub ahead of print]

PMID:
30230296
9.

Current Role of Checkpoint Inhibitors in Urologic Cancers.

Attalla K, Sfakianos JP, Galsky MD.

Cancer Treat Res. 2018;175:241-258. doi: 10.1007/978-3-319-93339-9_11.

PMID:
30168125
10.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.

Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.

11.

Dealing with perioperative antiplatelet treatment for transurethral resection of the bladder: primum non nocere.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2018 May;7(Suppl 2):S258-S259. doi: 10.21037/tau.2018.03.24. No abstract available.

12.

An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States.

Kaldany A, Blum KA, Paulucci DJ, Beksac AT, Jayaratna I, Sfakianos JP, Badani KK.

Urol Oncol. 2018 Aug;36(8):363.e1-363.e6. doi: 10.1016/j.urolonc.2018.05.006. Epub 2018 Jun 6.

PMID:
29884343
13.

Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.

Audenet F, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP, Galsky MD.

J Urol. 2018 Nov;200(5):996-1004. doi: 10.1016/j.juro.2018.06.001. Epub 2018 Jun 4.

PMID:
29879397
14.

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.

Audenet F, Farkas AM, Anastos H, Galsky MD, Bhardwaj N, Sfakianos JP.

World J Urol. 2018 Nov;36(11):1741-1748. doi: 10.1007/s00345-018-2359-7. Epub 2018 Jun 2.

PMID:
29860605
15.

Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.

Cha EK, Sfakianos JP, Sukhu R, Yee AM, Sjoberg DD, Bochner BH.

BJU Int. 2018 Oct;122(4):627-632. doi: 10.1111/bju.14242. Epub 2018 May 4.

PMID:
29633530
16.

The evolution of bladder cancer genomics: What have we learned and how can we use it?

Audenet F, Attalla K, Sfakianos JP.

Urol Oncol. 2018 Jul;36(7):313-320. doi: 10.1016/j.urolonc.2018.02.017. Epub 2018 Mar 21. Review.

PMID:
29573965
17.

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.

Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol Focus. 2018 Jan 30. pii: S2405-4569(18)30006-3. doi: 10.1016/j.euf.2018.01.005. [Epub ahead of print]

PMID:
29396293
18.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

PMID:
29358171
19.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
20.

Psychosocial impact of penile carcinoma.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2017 Oct;6(5):874-878. doi: 10.21037/tau.2017.07.24. Review.

21.

Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature.

Audenet F, Sfakianos JP.

Bladder Cancer. 2017 Oct 27;3(4):231-236. doi: 10.3233/BLC-170127. Review.

22.

Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.

Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK.

JCO Clin Cancer Inform. 2017 Nov;1:1-10. doi: 10.1200/CCI.17.00044.

23.

Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database.

Attalla K, Paulucci DJ, Blum K, Anastos H, Moses KA, Badani KK, Spiess PE, Sfakianos JP.

Urol Oncol. 2018 Jan;36(1):14.e17-14.e24. doi: 10.1016/j.urolonc.2017.09.014. Epub 2017 Oct 12.

PMID:
29031418
24.

Management of Atypical Renal Cell Carcinomas.

Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK.

Curr Treat Options Oncol. 2017 Sep 14;18(10):61. doi: 10.1007/s11864-017-0501-1. Review.

PMID:
28913767
25.

Heterogeneity in renal cell carcinoma.

Beksac AT, Paulucci DJ, Blum KA, Yadav SS, Sfakianos JP, Badani KK.

Urol Oncol. 2017 Aug;35(8):507-515. doi: 10.1016/j.urolonc.2017.05.006. Epub 2017 May 24. Review.

PMID:
28551412
26.

Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?

Galsky MD, Sfakianos JP, Ferket BS.

Eur Urol. 2017 Oct;72(4):555-556. doi: 10.1016/j.eururo.2017.04.012. Epub 2017 Apr 19. No abstract available.

PMID:
28433377
27.

Predicting Complications Following Robot-Assisted Partial Nephrectomy with the ACS NSQIP® Universal Surgical Risk Calculator.

Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD, Bhandari A, Hemal AK, Sfakianos JP, Badani KK.

J Urol. 2017 Oct;198(4):803-809. doi: 10.1016/j.juro.2017.04.021. Epub 2017 Apr 9.

PMID:
28400189
28.

Trends in management of the small renal mass in renal transplant recipient candidates: A multi-institutional survey analysis.

Beksac AT, Paulucci DJ, Sfakianos JP, Reddy BN, Gin GE, Lerner SM, Badani KK.

Urol Oncol. 2017 Aug;35(8):529.e17-529.e22. doi: 10.1016/j.urolonc.2017.03.012. Epub 2017 Apr 5.

PMID:
28391999
29.

Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma.

Gin GE, Ruel NH, Kardos SV, Sfakianos JP, Uchio E, Lau CS, Yuh BE.

Urol Oncol. 2017 May;35(5):192-200. doi: 10.1016/j.urolonc.2016.11.017. Epub 2016 Dec 29.

PMID:
28041996
30.

Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma.

Paulucci DJ, Sfakianos JP, Skanderup AJ, Kan K, Tsao CK, Galsky MD, Hakimi AA, Badani KK.

Oncotarget. 2017 Jan 17;8(3):5196-5205. doi: 10.18632/oncotarget.14122.

31.

Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.

Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.

Urol Oncol. 2017 Apr;35(4):151.e9-151.e15. doi: 10.1016/j.urolonc.2016.11.002. Epub 2016 Dec 5.

32.

Leiomyosarcoma of the Inferior Vena Cava With Kidney Invasion.

Brewer K, Attalla K, Husain F, Tsao CK, Badani KK, Sfakianos JP.

Urol Case Rep. 2016 Sep 23;9:33-6. doi: 10.1016/j.eucr.2016.08.011. eCollection 2016 Nov.

33.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

34.

R.E.N.A.L. Nephrometry Score Predicts Non-neoplastic Parenchymal Volume Removed During Robotic Partial Nephrectomy.

Husain FZ, Rosen DC, Paulucci DJ, Sfakianos JP, Abaza R, Badani KK.

J Endourol. 2016 Oct;30(10):1099-1104.

PMID:
27604690
35.

Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?

Galsky MD, Domingo-Domenech J, Sfakianos JP, Ferket BS.

J Clin Oncol. 2016 Oct 10;34(29):3495-3498. doi: 10.1200/JCO.2016.68.3714. Review.

PMID:
27551117
36.

Selective arterial clamping does not improve outcomes in robot-assisted partial nephrectomy: a propensity-score analysis of patients without impaired renal function.

Paulucci DJ, Rosen DC, Sfakianos JP, Whalen MJ, Abaza R, Eun DD, Krane LS, Hemal AK, Badani KK.

BJU Int. 2017 Mar;119(3):430-435. doi: 10.1111/bju.13614. Epub 2016 Aug 31.

37.

Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.

38.

Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices.

Mohamed NE, Pisipati S, Lee CT, Goltz HH, Latini DM, Gilbert FS, Wittmann D, Knauer CJ, Mehrazin R, Sfakianos JP, McWilliams GW, Quale DZ, Hall SJ.

Urol Oncol. 2016 Dec;34(12):531.e7-531.e14. doi: 10.1016/j.urolonc.2016.06.010. Epub 2016 Jul 19.

PMID:
27449687
39.

Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.

Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B.

J Clin Oncol. 2016 Aug 1;34(22):2627-35. doi: 10.1200/JCO.2016.67.5033. Epub 2016 Jun 6.

40.

Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes.

Sankin A, Tin AL, Mano R, Chevinsky M, Jakubowski C, Sfakianos JP, Cha EK, Yee A, Friedman FM, Sjoberg DD, Ehdaie B, Coleman J.

Urology. 2016 Aug;94:148-53. doi: 10.1016/j.urology.2016.05.039. Epub 2016 May 26.

41.

Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.

Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD.

Eur Urol. 2016 Nov;70(5):771-775. doi: 10.1016/j.eururo.2016.04.037. Epub 2016 May 10.

42.

Emerging surgical treatments for renal cell carcinoma.

Husain FZ, Badani KK, Sfakianos JP, Mehrazin R.

Future Oncol. 2016 Apr;12(7):921-9. doi: 10.2217/fon.15.362. Epub 2016 Feb 19. Review.

PMID:
26892144
43.

BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas.

Paulucci DJ, Sfakianos JP, Yadav SS, Badani KK.

Urol Oncol. 2016 Jun;34(6):259.e9-259.e14. doi: 10.1016/j.urolonc.2015.12.019. Epub 2016 Feb 4.

PMID:
26854086
44.

Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.

Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP.

J Clin Oncol. 2016 Mar 10;34(8):825-32. doi: 10.1200/JCO.2015.64.1076. Epub 2016 Jan 19.

PMID:
26786930
45.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA, Iyer G, Scott SN, Shah R, Ostrovnaya I, Lee B, Desai NB, Ren Q, Rosenberg JE, Dalbagni G, Bajorin DF, Reuter VE, Berger MF; Collaborators.

J Urol. 2016 Jun;195(6):1684-1689. doi: 10.1016/j.juro.2016.01.006. Epub 2016 Jan 14.

46.

Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: A survey of U.S. transplantation centers.

Gin GE, Pereira JF, Weinberg AD, Mehrazin R, Lerner SM, Sfakianos JP, Phillips CK.

Urol Oncol. 2016 Feb;34(2):57.e9-13. doi: 10.1016/j.urolonc.2015.08.020. Epub 2015 Oct 1.

PMID:
26433443
47.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol. 2015 Dec;68(6):970-7. doi: 10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14.

48.

Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates.

Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE.

J Urol. 2015 Dec;194(6):1567-74. doi: 10.1016/j.juro.2015.06.077. Epub 2015 Jun 19.

49.

Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.

Sfakianos JP, Galsky MD.

Urol Clin North Am. 2015 May;42(2):181-7, viii. doi: 10.1016/j.ucl.2015.01.002. Epub 2015 Mar 5. Review.

PMID:
25882560
50.

Comparison of perioperative outcomes for epidural versus intravenous patient-controlled analgesia after radical cystectomy.

Winer AG, Sfakianos JP, Puttanniah VG, Bochner BH.

Reg Anesth Pain Med. 2015 May-Jun;40(3):239-44. doi: 10.1097/AAP.0000000000000219.

Supplemental Content

Loading ...
Support Center